📊 XTNT Key Takeaways
Is Xtant Medical Holdings, Inc. (XTNT) a Good Investment?
Xtant Medical is a growth-stage medical device company achieving strong 14.2% revenue growth and healthy 57.3% gross margins, but remains unprofitable with negative operating cash flow (-$2.1M) and is destroying shareholder value (ROE: -6.4%). While improving loss trajectory and low leverage provide runway, the company's inability to convert strong gross margins to operating profitability signals fundamental operational challenges that must be resolved.
Xtant Medical Holdings, Inc. Key Strengths (XTNT)
- Revenue growth of 14.2% YoY demonstrates market demand and expansion
- Gross margin of 57.3% indicates strong product/pricing power in medical devices
- Improving loss profile with net income improving 130.2% YoY toward breakeven
- Strong balance sheet with low debt-to-equity ratio of 0.17x and good liquidity ratios (current: 3.34x, quick: 1.64x)
- Total assets of $78M and stockholders equity of $48.6M provide adequate financial base
XTNT Stock Risks: Xtant Medical Holdings, Inc. Investment Risks
- Negative operating cash flow (-$2.1M) and free cash flow (-$2.3M) indicate the business is not self-sustaining
- Operating margin of -14% and net margin of -14.8% with negative ROE (-6.4%) and ROA (-4.0%) indicate value destruction
- Negative interest coverage ratio of -4.9x means operating losses prevent debt service from operations
- Cash runway of approximately 5 years at current burn rate with only $12.1M cash on hand
- Gap between strong gross margins and negative operating income suggests unresolved operational or cost structure issues
Key Metrics to Watch
- Operating cash flow trend toward positive territory (critical inflection point)
- Path to operating profitability and timeline to achieve positive net income
- Operating expense ratio as percentage of revenue (can they achieve operational leverage?)
- Cash burn rate and runway extension through profitability or capital raises
- Gross margin sustainability as company scales production
Xtant Medical Holdings, Inc. (XTNT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.34x current ratio provides a solid financial cushion.
XTNT Profit Margin, ROE & Profitability Analysis
XTNT vs Healthcare Sector: How Xtant Medical Holdings, Inc. Compares
How Xtant Medical Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xtant Medical Holdings, Inc. Stock Overvalued? XTNT Valuation Analysis 2026
Based on fundamental analysis, Xtant Medical Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xtant Medical Holdings, Inc. Balance Sheet: XTNT Debt, Cash & Liquidity
XTNT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xtant Medical Holdings, Inc.'s revenue has grown significantly by 142% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.12 indicates the company is currently unprofitable.
XTNT Revenue Growth, EPS Growth & YoY Performance
XTNT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.9M | $58.0K | $0.00 |
| Q3 2025 | $27.9M | $58.0K | $0.01 |
| Q2 2025 | $29.9M | $58.0K | $0.02 |
| Q1 2025 | $27.9M | $58.0K | $0.00 |
| Q3 2024 | $25.0M | -$2.1M | $0.04 |
| Q2 2024 | $20.2M | -$2.1M | $-0.02 |
| Q1 2024 | $17.9M | -$2.1M | $-0.02 |
| Q3 2023 | $14.5M | -$1.7M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xtant Medical Holdings, Inc. Dividends, Buybacks & Capital Allocation
XTNT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xtant Medical Holdings, Inc. (CIK: 0001453593)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XTNT
What is the AI rating for XTNT?
Xtant Medical Holdings, Inc. (XTNT) has an AI grade of C with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XTNT's key strengths?
Claude: Revenue growth of 14.2% YoY demonstrates market demand and expansion. Gross margin of 57.3% indicates strong product/pricing power in medical devices.
What are the risks of investing in XTNT?
Claude: Negative operating cash flow (-$2.1M) and free cash flow (-$2.3M) indicate the business is not self-sustaining. Operating margin of -14% and net margin of -14.8% with negative ROE (-6.4%) and ROA (-4.0%) indicate value destruction.
What is XTNT's revenue and growth?
Xtant Medical Holdings, Inc. reported revenue of $20.9M.
Does XTNT pay dividends?
Xtant Medical Holdings, Inc. does not currently pay dividends.
Where can I find XTNT SEC filings?
Official SEC filings for Xtant Medical Holdings, Inc. (CIK: 0001453593) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XTNT's EPS?
Xtant Medical Holdings, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is XTNT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Xtant Medical Holdings, Inc. has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is XTNT stock overvalued or undervalued?
Valuation metrics for XTNT: ROE of -6.4% (sector avg: 15%), net margin of -14.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is XTNT's AI grade for 2026?
Our dual AI analysis gives Xtant Medical Holdings, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XTNT's free cash flow?
Xtant Medical Holdings, Inc.'s operating cash flow is $-2.1M, with capital expenditures of $194.0K. FCF margin is -11.1%.
How does XTNT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14.8% (avg: 12%), ROE -6.4% (avg: 15%), current ratio 3.34 (avg: 2).